ScholarIQanswers from OpenAlex
Opexa Therapeutics (United States)
InstitutionResearch output, impact & collaborations
Opexa Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.
What is known about Opexa Therapeutics (United States)?
ScholarIQrecord summary
Opexa Therapeutics (United States) is a research organisation in The Woodlands, US. OpenAlex records 454 works and 24,445 citations for it. 191 researchers list it as their most recent affiliation.
How many works does Opexa Therapeutics (United States) have?
ScholarIQindexed works
Opexa Therapeutics (United States) has 454 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Opexa Therapeutics (United States) have?
ScholarIQcitation count
Opexa Therapeutics (United States) has 24,445 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Opexa Therapeutics (United States)?
ScholarIQresearcher count
Opexa Therapeutics (United States) has 191 researchers in the ScholarIQ index.
What is the average h-index at Opexa Therapeutics (United States)?
ScholarIQavg h-index
Opexa Therapeutics (United States) has an average h-index of 49.5 in OpenAlex.
What is the ROR of Opexa Therapeutics (United States)?
ScholarIQror
The ROR for Opexa Therapeutics (United States) is on the source record.
What is the OpenAlex record for Opexa Therapeutics (United States)?
ScholarIQopenalex
The OpenAlex for Opexa Therapeutics (United States) is on the source record.
Who are the most-cited researchers behind Opexa Therapeutics (United States)?
ScholarIQtop researchers by citations
What are the most-cited papers on Opexa Therapeutics (United States)?
ScholarIQmost cited works
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Nicole Concin, Xavier Matías‐Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan A. Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio González-Martı́n, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A. Nout, D. O’Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke M. Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Carien L. Creutzberg
How much of the research on Opexa Therapeutics (United States) is open access?
ScholarIQopen access share
83%OPEN ACCESS